MAP2K7 and uveal melanoma: Another inhibitor of the MEK family, trametinib, was under evaluation in a phase I study (56) but demonstrated limited clinical efficacy against previously treated metastatic uveal melanomas (PFS of 1.8 months and global response rates of approximately 0%).